Breadcrumb

DSI Business Development

Daiichi Sankyo Business Development

Daiichi Sankyo Group is dedicated to the creation and supply of innovative pharmaceutical products to address diversified, unmet medical needs of patients in both mature and emerging markets. With over 100 years of scientific expertise and a presence in more than 20 countries, Daiichi Sankyo and its 15,000 employees around the world draw upon a rich legacy of innovation and a robust pipeline of promising new medicines to help people.

In addition to a strong portfolio of medicines for hypertension and thrombotic disorders, under the Group’s 2025 Vision to become a “Global Pharma Innovator with a Competitive Advantage in Oncology”, Daiichi Sankyo Research and Development is primarily focused on bringing forth novel therapies in oncology, including immuno-oncology, with additional focus on new horizon areas, such as pain management, neurodegenerative diseases, heart and kidney conditions, and other rare diseases.

To reinforce the competitiveness of research in these areas, we are partnering on promising products that complement our in-house portfolio and will help us achieve long-term growth.  With a long-history of effective collaboration, our strategy involves partnering on specific aspects of research, development and/or commercialization. Click to download Daiichi Sankyo Areas of Interest

Partner with Daiichi Sankyo

We expect our employees to demonstrate a passion and drive that is consistent with our company's strategy and vision. Do you share these values? Are you interested in learning how to partner with Daiichi Sankyo? Please contact us to start a conversation about how we can work together to improve patient lives through the development of high-quality pharmaceutical products.

We have business development colleagues located globally, in Tokyo, Japan, in the United States (Basking Ridge, New Jersey), and in Europe (Munich, Germany). Please submit your licensing or alliance proposal for consideration.

Regional Commercial Interests

Japan

  • Late-stage or marketed products in Central Nervous System (CNS), Cardiovascular (CV) or Oncology for Japan commercialization

United States

  • Late-stage or marketed products/pipeline in Specialty Care for US commercialization

European Union

  • Late-stage or marketed products in Specialty Care for EU commercialization

 

PP

PP-US-NP-1327  11/20

-US-NP-0276 09/2017

Company Culture More Stories

Learn More

Who We Are

As the U.S. subsidiary of a global pharmaceutical innovator, Daiichi Sankyo, Inc. draws on a rich heritage of innovation, integrity and accountability.

read more ...

Business Development Helpful Resources